Figure 1. Ruxolitinib.
As a specific inhibitor of JAK1 and JAK2, the drug targets the ATP- binding pocket of each kinase, including the mutated JAK2V617F form.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.